Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2011-01-31
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metabolic Impact of Fructose Restriction in Obese Children
NCT01200043
Dietary Fructose: a Metabolic Switch in Pediatric Obesity-related Disease.
NCT06365567
Meta-analyses of the Effect of Important Food Sources of Sugars on Cardiometabolic Risk Factors
NCT02716870
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
NCT02558920
Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases
NCT02702375
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Most studies on "fetal origins" of obesity in the offspring have focused on maternal high-fat diets; yet dietary fat consumption has not changed appreciably in the last two decades. One chemical exposure in both pregnant mothers and newborns that has been steadily increasing worldwide is fructose. Although ostensibly a carbohydrate, fructose is a potent lipogenic substrate, and in the hypercaloric state, as much as 30% of an ingested fructose load undergoes de novo lipogenesis to form triglyceride thus the effects of high-fat and high-fructose diets in terms of physiology and outcome are comparable. Substituting sucrose (fructose + glucose) for glucose alone increases visceral adiposity, insulin resistance, and dyslipidemia in adult animals and humans. For humans, fructose is ubiquitous in the food environment, especially for pregnant mothers, who are often counseled to drink juice during pregnancy, as it is deemed to be healthier than soda. The effects of fructose consumption during pregnancy on infant birth weight and adiposity has not yet been studied.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Plans to remain in the area through delivery
* Ability to understand and give informed consent in either English or Spanish.
Exclusion Criteria
* Presence of gestational diabetes during a previous pregnancy
* Presence of diabetes or of other chronic metabolic disease such as cardiovascular disease, active thyroid disease, liver disease, pulmonary or psychiatric disorders, HIV
* Any disorder requiring diet therapy (i.e., renal insufficiency)
* Multiple gestation
* Prior history of intrauterine growth retardation
* Use of substances known to cause intrauterine growth retardation (e.g., smoking or drug use). -
* Once recruited, any ultrasonographic evidence of intrauterine growth retardation during the course of the pregnancy would also lead to exclusion.
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
San Francisco General Hospital
OTHER
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Lustig, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Anjali Jain, MD
Role: STUDY_DIRECTOR
University of California, San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Francisco General Hospital
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SFGH 6281
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.